Cited by 146Genomic variations and chromosomal abnormalitiesGenetics and Neurodevelopmental DisordersGenomics and Rare Diseases

The de novo chromosome 16 translocations of two patients with abnormal phenotypes (mental retardation and epilepsy) disrupt the A2BP1 gene

Bhalla, Kavita, Phillips, Hilary A., Crawford, Joanna, McKenzie, Olivia L. D., Mulley, John C., Eyre, Helen, Gardner, Alison E., Kremmidiotis, Gabriel +1 more·2004·Journal of Human Genetics

Abstract

The 16p13.3 breakpoints of two de novo translocations of chromosome 16, t(1;16) and t(14;16), were shown by initial mapping studies to have physically adjacent breakpoints. The translocations were ascertained in patients with abnormal phenotypes characterized by predominant epilepsy in one patient and mental retardation in the other. Distamycin/DAPI banding showed that the chromosome 1 breakpoint of the t(1;16) was in the pericentric heterochromatin therefore restricting potential gene disruption to the 16p13.3 breakpoint. The breakpoints of the two translocations were localized to a region of 3.5 and 115 kb respectively and were approximately 900 kb apart. The mapping was confirmed by fluorescence in situ hybridization (FISH) of clones that spanned the breakpoints to metaphase spreads derived from the patients. The mapping data showed both translocations disrupted the ataxin-2-binding protein 1 ( A2BP1) gene that encompasses a large genomic region of 1.7 Mb. A2BP1 encodes a protein that is known to interact with the spinocerebellar ataxia type 2 ( SCA2) protein. It is proposed that disruption of the A2BP1 gene is a cause of the abnormal phenotype of the two patients. Ninety-six patients with sporadic epilepsy and 96 female patients with mental retardation were screened by SSCP for potential mutations of A2BP1. No mutations were found, suggesting that disruption of the A2BP1 gene is not a common cause of sporadic epilepsy or mental retardation.

Integrity signals

Registry

Crossref · 10.1007/s10038-004-0145-4

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Together with neuro-developmental defects seen in cell cultures, animal models, and human patients with disrupted Rbfox proteins, this provides a compelling case that Rbfox proteins play critical roles in driving the global dynamic change of the developmental splicing-regulatory program.

    “Combined with neuro-developmental defects observed in cell cultures (Kim et al., 2013), animal models (Gehman et al., 2012; Gehman et al., 2011; Kim et al., 2013), and human patients (Bhalla et al., 2004) where Rbfox proteins are disrupted, this presents a compelling case for Rbfox proteins playing critical roles in driving the global dynamic change of the developmentalsplicing-regulatory program.”
  • Human mutations in RBFOX1 have been identified in patients with epilepsy.

    “Human mutations in RBFOX1 have been identified in patients with epilepsy126–128”

    From The neurogenetics of alternative splicing (2016) · cites this paper as [126]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bhalla, K., Phillips, H. A., Crawford, J., McKenzie, O. L. D., Mulley, J. C., Eyre, H., Gardner, A. E., Kremmidiotis, G., & Callen, D. F.
Affiliations
  • Women's and Children's Hospital (AU)
  • South Australia Pathology (AU)
Corresponding author
Callen, David F.
Venue
Journal of Human Genetics
Published
2004-05-18
Volume
49
Issue
6
Pages
308-311
ISSN
  • 1434-5161 (ISSN-L)
  • 1435-232X
OpenAlex
W2086863891
Cited by
146
References
6
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 10 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 11 · 2015: 6 · 2014: 12 · 2013: 12 · 2012: 6
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Human Genetics (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
gene disruption, epilepsy, intellectual disability, spinocerebellar ataxia type 2, pericentromeric heterochromatin, breakpoint mapping, fluorescence in situ hybridization
MeSH terms
Ataxins, RNA Splicing Factors, Adolescent, Child, Preschool, Chromosome Mapping, Chromosomes, Human, Pair 16, Epilepsy, Exons, Female, Humans, Introns, Male, Intellectual Disability, Models, Genetic, Mutation, Nerve Tissue Proteins, Phenotype, Proteins, Translocation, Genetic, RNA-Binding Proteins, In Situ Hybridization, Fluorescence, Polymorphism, Single-Stranded Conformational, Physical Chromosome Mapping

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review